A new kid on the block: PKD1: a promising target for antiangiogenic therapy?
Altschmied
Joachim
J
Haendeler
Judith
J
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D042783:Endothelial Cells / Q000187:drug effects* / Q000201:enzymology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006655:Histone Deacetylases / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D053506:Matrix Metalloproteinase 10 / Q000378:metabolism; D053511:Matrix Metalloproteinase 14 / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010766:Phosphorylation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; C089212:protein kinase D; D011493:Protein Kinase C; C511770:MMP10 protein, human; D053506:Matrix Metalloproteinase 10; C507086:MMP14 protein, human; D053511:Matrix Metalloproteinase 14; C543273:HDAC7 protein, human; D006655:Histone Deacetylases